Inovio Pharmaceuticals(US:INO) TMX Newsfile·2026-03-22 02:22Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by visiting the provided link or contacting the firm directly [3][6]. - The deadline to move the Court to serve as lead plaintiff is April 7, 2026, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Inovio made false and misleading statements regarding the manufacturing of its CELLECTRA device and the likelihood of submitting the INO-3107 Biologics License Application to the FDA by the second half of 2024 [5]. - It is claimed that Inovio lacked sufficient information to justify the INO-3107 BLA's eligibility for FDA accelerated approval, leading to overstated regulatory and commercial prospects [5].